Unprecedented Early-Stage Cancer Detection Presented at AACR 2026
Dxcover Highlights Liquid Biopsy Platform Performance in Multiple Settings Glasgow, UK, April 2, 2026 — Dxcover, a global leader in…
Dxcover Secures CE-IVDR Certification
Key Milestone Signals Readiness for Regulated Diagnostic Deployment Glasgow, UK, March 3, 2026 — Dxcover, a global leader in AI-enabled…
New Blood Test Helps GPs Manage Brain Scan Delays, Brings Field Forward
GLASGOW, UK, February 13, 2026 — Dxcover, a global leader in innovative AI-enabled technologies, today announced the availability of its…
Dxcover Strengthens Leadership with World-Class Scientific Advisors and Board Members
Date: 04 August 2025 – GLASGOW, Scotland – Dxcover, a clinical-stage oncology diagnostics company developing and commercializing its Multiomic Spectral…
Dxcover launches US operations to commercialize its AI-powered multiomic cancer detection test
Date: 24 June 2025 Opens U.S. headquarters in Nashville – a leading healthcare and life sciences hub Building the foundation…
Dxcover Announces Global Presentation Of First Real-World Evidence Demonstrating That Increased Tumour Size Is Associated With Higher Mortality In Patients With Brain Cancer
GLASGOW, Scotland (April 30, 2025) Dxcover Limited, a clinical-stage diagnostics company pioneering its multiomic spectral analysis (MOSA-Dx™) for early detection…
Dxcover Accelerates Growth With New Funding Round and Strengthens The Leadership Team
February 03, 2025 09:00 AM GMT New capital raise from existing investors, as well as new investors, Macmillan Cancer Support…
Dxcover names first US Scientific Advisory Board Member
Luke Pike MD, DPhil, Radiation Oncologist, joins Dxcover Scientific Advisory Board to advise the company on brain cancer diagnostic early…
Dxcover Recognised for Scientific Excellence at ADLM2024
Distinguished Abstract Award to be presented Wednesday July 31 at Academy of Diagnostics & Laboratory Medicine Annual Meeting in Chicago.…